Blood Cancers | Tumor

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

December 6th 2020, 7:30pm

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Drug Duo Granted Priority Review to Treat Waldenstrom Macroglobulinemia

June 25th 2018, 6:50pm

Article

The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.

Latest News

Helping Women of Color Thrive Beyond Cancer Treatment

Facing Lung Cancer with Grace and Self-Compassion

Long Delays Seen in Essential Thrombocythemia Diagnosis After Platelet Rise

A Little Off the Top: the First Step in a Brain Cancer Journey

View More Latest News